A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies
Status:
Suspended
Trial end date:
2024-09-02
Target enrollment:
Participant gender:
Summary
This dose-escalation study evaluating the safety, pharmacokinetics and preliminary efficacy
of venetoclax in combination with AMG 176 in participants with relapsed or refractory acute
myeloid leukemia (AML) and participants with Non-Hodgkin's lymphoma (NHL)/diffuse large
B-cell lymphoma (DLBCL).
This study will include a dose escalation phase to identify the maximum tolerated
dose/recommended phase 2 dose (MTD/RPTD) of venetoclax plus AMG 176 as well as a dose
expansion phase to confirm safety, explore efficacy, and confirm the suitability of the
preliminary RPTD.